Clinical Trial Update: Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) [Phase 4]

View source ↗

Summary

Phase 4 post-marketing safety study assessing Omniscan (gadodiamide) safety in patients with moderate renal insufficiency undergoing contrast-enhanced MRI; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• OMNISCAN (gadodiamide)

Snippet

Sponsor: GE Healthcare | Conditions: Chronic Kidney Disease, Renal Insufficiency | Phase 4 | Status: COMPLETED | Results posted: 2014-07-17